SOURCE: TheSUBWAY.com

January 25, 2006 08:56 ET

Morning Stock Focus List for Wednesday, January 25, 2006: Proceeds to Be Used for Further Restructuring and to Launch Sickle Cell Drug!

NOTE TO EDITORS: The Following Is an Investment Opinion Being Issued by Peter Antipatis of Capital Research Group Inc.

WESTON, FL -- (MARKET WIRE) -- January 25, 2006 -- TheSUBWAY.com names the following stocks to its Stock Focus List: Xechem International Inc. (OTC BB: XKEM), Capstone Turbine Corporation (NASDAQ: CPST), Vitesse Semiconductor Corp. (NASDAQ: VTSS), Google Inc. (NASDAQ: GOOG).

Xechem International, Inc. (OTC BB: XKEM), Xechem International said today that the $4.2 million settlement of its antitrust lawsuit against Bristol-Meyers Squibb Co., announced December 2005, has closed and that the net settlement proceeds have now been received by the company.

Xechem International, Inc. is a development stage biopharmaceutical company focusing on anticancer, antiviral (including AIDS), antifungal, Sickle Cell Disease (SCD), antimalarial and antibacterial products from natural sources, including microbial and marine organisms.

Other stocks highlighted include Capstone Turbine Corporation (NASDAQ: CPST): Stock Focus List, up 8% on 13 million shares, Vitesse Semiconductor Corp. (NASDAQ: VTSS): Stock Focus List, up 23% on 44 million shares, Google Inc. (NASDAQ: GOOG): Stock Focus List, up 4% on 15 million shares.

"A few disappointing earnings releases and some disparate economic data have done their part to stall the market's advance, and political developments abroad have kept investors cautious. But overall tame inflation numbers, though rising over the past few months, solid growth in the domestic economy, and lower unemployment are buffeting the averages from below." More is available at: http://www.thesubway.com/sub_comm.asp.

TheSUBWAY.com's Daily Stock Updates:

TheSUBWAY.com, a leader in corporate communications and finance, highlights stocks that are in the news, have traded high volume, or experienced a large change in price in recent sessions. The aforementioned commentary is not meant to be indicative of a "long term" view of any of the companies listed. For more go to http://www.thesubway.com/sub_comm.asp.

All material herein was prepared by Capital Research Group, Inc. (CRG) based upon information believed to be reliable. The information contained herein is not guaranteed by CRG to be accurate, and should not be considered to be all-inclusive. The companies that are discussed in this opinion have not approved the statements made in this opinion. This opinion contains forward-looking statements that involve risks and uncertainties. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. CRG is not a licensed broker, broker dealer, market maker, investment banker, investment advisor, analyst or underwriter. Please consult a broker before purchasing or selling any securities viewed on http://www.thesubway.com or mentioned herein. CRG has been compensated by third party shareholders or with cash from the company on behalf of one or more of the companies mentioned in this opinion. CRG has been compensated twenty thousand dollars for XKEM. CRG was compensated one hundred twenty thousand dollars in past compensation for XKEM. CRG intends to sell its shares. CRG has sold approximately zero XKEM shares to date. CRG may sell its shares for less than the target price given in this opinion. In addition to any compensation mentioned above, additional compensation can be equal to ten percent of any newly issued or registered securities of the profiled companies. CRG's affiliates, officers, directors and employees may also have bought or may buy the shares discussed in this opinion and may profit in the event those shares rise in value. CRG will not advise as to when it decides to sell and does not and will not offer any opinion as to when others should sell; each investor must make that decision based on his or her judgment of the market.

Contact Information

  • Chuck Tamburello
    Phone: 954-217-8555
    Fax: 954-217-1500